Drug major GlaxoSmithKline (GSK) has unethically tested a breast cancer drug on poor patients in India for approval for new drugs in the Europe Union, said a study. According to an investigation by Mumbai-based Centre for Studies in Ethics and Rights, the firm tested lapatinib on patients flouting Indian Council of Medical Research's (ICMR) ethical guidelines.This trial required seriously ill patients who had not received treatment for their condition.
GlaxoSmithKline on Wednesday applied for approval to market its breast cancer drug Tykerb in U.S. and Europe as a first-line treatment for women with advanced, hormone-sensitive breast cancer, the AP/Google.com reports. Tykerb, know... Read Post
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (... Read Post